このエントリーをはてなブックマークに追加
ID 40503
JaLCDOI
FullText URL
Author
Nishimori, Hisakazu
Takahashi, Shunji
Ennishi, Daisuke
Kobayashi, Takayuki
Sano, Koji
Shinozaki, Eiji
Yokoyama, Masahiro
Mishima, Yuko
Terui, Yasuhito
Chin, Keisho
Mizunuma, Nobuyuki
Ito, Yoshinori
Nishimura, Seiichiro
Takeuchi, Kengo
Ishikawa, Yuichi
Oguchi, Masahiko
Hatake, Kiyohiko
Abstract
We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.
Keywords
cancer of unknown primary site (CUP)
cisplatin
docetaxel
prognosis
Amo Type
Original Article
Published Date
2010-10
Publication Title
Acta Medica Okayama
Volume
volume64
Issue
issue5
Publisher
Okayama University Medical School
Start Page
285
End Page
291
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
Copyright Holders
CopyrightⒸ 2010 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID
Web of Science KeyUT